Deepnoid Demonstrates Clinical Efficacy of M4CXR

Deepnoid is garnering attention as a demonstration-based company aligned with the new government's Physical AI promotion policy, leveraging its technological capabilities in developing generative medical artificial intelligence (AI) software.

On July 14, Deepnoid announced that it had demonstrated the practical applicability of generative AI in real-world settings through its generative AI-based CXR report draft generation model, 'M4CXR'.

The entire process, from image input to the generation of a report draft, is autonomously handled by AI. The company has proven the effectiveness and utility of its technology in actual clinical environments. At ESTI 2025 (European Society of Thoracic Imaging Annual Meeting) held in June, three related research papers were accepted as abstracts. The company also received the Best Oral Presentation Award, gaining international recognition for its technological prowess.

The government views Physical AI as a core technology to drive the digital transformation of real industries such as manufacturing, logistics, construction, and healthcare. This year, a budget of 42.6 billion KRW has been allocated for the proof-of-concept (POC) of core Physical AI technologies. At the 'AI G3 Powerhouse New Technology Strategy Breakfast Forum' held in the National Assembly, plans for large-scale R&D projects, including Physical AI, were unveiled. Deepnoid CEO Choi Woosik attended as an industry representative and shared challenges faced in the medical and security sectors.

As technological advancements and policy directions converge, interest in Deepnoid's mid- to long-term growth potential is increasing. In a report published in February, SK Securities positively evaluated the company, stating, "Deepnoid is a noteworthy company for the potential popularization of generative AI-based medical devices."

Currently, Deepnoid is preparing for the clinical trial approval (IND) process for 'M4CXR' with the Ministry of Food and Drug Safety. The company is focusing on advancing its technology to commercialize generative AI-based medical devices. Based on this, it plans to expand its application scope to the industrial Physical AI sector in the future.

A Deepnoid representative explained, "We are currently accelerating the clinical trial approval process for M4CXR with the Ministry of Food and Drug Safety," and added, "We are concentrating all our resources on commercializing generative AI-based medical devices." The representative continued, "We expect to expand into the industrial Physical AI sector as well."